Provided by Tiger Trade Technology Pte. Ltd.

California Resources

53.03
+0.80001.53%
Pre-market: 54.091.06+2.00%04:25 EDT
Volume:553.10K
Turnover:29.24M
Market Cap:4.70B
PE:-37.78
High:53.56
Open:53.16
Low:52.20
Close:52.23
52wk High:71.98
52wk Low:43.25
Shares:88.60M
Float Shares:83.56M
Volume Ratio:0.82
T/O Rate:0.66%
Dividend:1.60
Dividend Rate:3.02%
EPS(TTM):-1.4038
EPS(LYR):4.15
ROE:-3.55%
ROA:0.76%
PB:1.38
PE(LYR):12.78

Loading ...

Final decision on open consultation on methodology for US CRC, HDG, plate

Fastmarkets
·
Jun 15

California Resources Corp (CRC) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Jun 15

A Look At California Resources (CRC) Valuation After Recent Share Price Cooling

Simply Wall St.
·
Jun 11

California Resources EVP, Chief Commercial Officer Jay A. Bys disposes of 11,907 shares worth $734,036.76

Reuters
·
Jun 06

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

GlobeNewswire
·
Jun 03

California Resources outlines oil and gas strategy, carbon capture growth in corporate presentation

Reuters
·
Jun 02

Does First Carbon TerraVault CO2 Injection Reshape the Bull Case for California Resources (CRC)?

Simply Wall St.
·
May 30

Analysts Are Bullish on These Energy Stocks: Canadian Natural (CNQ), California Resources Corp (CRC)

TIPRANKS
·
May 28

Abbott: ACS releases updated CRC guidelines reaffirm Cologuard, Cologuard Plus

TIPRANKS
·
May 27

California Resources price target raised to $87 from $86 at Mizuho

TIPRANKS
·
May 27

U.S. RESEARCH ROUNDUP- Agilent Technologies, Fedex, Synopsys

Reuters
·
May 27

California Resources Is Maintained at Overweight by Barclays

Dow Jones
·
May 27

Roth MKM Sticks to Their Buy Rating for California Resources Corp (CRC)

TIPRANKS
·
May 26

California Resources Corporation Achieves First CO₂ Injection at Carbon TerraVault I, a Major Milestone for Carbon Management in California

GlobeNewswire
·
May 26

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

GlobeNewswire
·
May 26

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

GlobeNewswire
·
May 22

Partner Inhibrx Reports Positive CRC Data for Ozekibart and Submits US BLA for Chondrosarcoma Treatment

Stock News
·
May 21

California Resources Raised to Buy From Neutral by Citigroup

Dow Jones
·
May 20

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

GlobeNewswire
·
May 20

BUZZ-Citigroup raises PT on US energy companies

Reuters
·
May 20